Introduction/Background Human Papillomavirus (HPV) DNA detection is a sensitive technique for cervical cancer screening but its specificity remains limited.

New molecular tests are available, easy to use. In our study we used The OncoE6 test to detect E6 Oncoprotein from cervical specimens.

The aim is to establish the HPV genotype profil in cervical cancer patients in Casablanca, and compare the results of genotyping with the OncoE6 test results. So we can determin the feasibility of a screening with the new HPV generation test in Morocco.

Methodology It's cross-sectional study that was conducted at Mohammed VI Center for Cancer treatment. The study included patients newly diagnosed with cervical cancer. Patients who received previous treatment (surgery, chemotherapy, radiotherapy) were excluded.

Two samples were taken from the cervix for each patient, One sent to Berlin for multiplex Polymerase Chain Reaction (PCR) genotyping, second samples were analyzed in Casablanca by a different investigator, using the OncoE6 test.

Results Thirty patients were included in our study. The average age was 58,65±11,83. The histopathological examination showed Squamous Cell Carcinoma in 80% of the cases and Adenocarcinoma in 20%.

The OncoE6 test was positive in the two thirds of cases. 42% of the cases tested positive to the Oncoprotein E6 HPV 16 type, and 23% were positive to the OncoE6 HPV 18 type.

Genotyping revealed the presence of 12 serotypes of High Risk HPV, the most frequent was HPV 16. In 7 cases there was more than one serotype.

For the patients who tested negative to the OncoE6 test, the genotyping identified 8 different high risk HPV apart from HPV 16 and 18.

Conclusion High risk HPV serotypes found in our patients apart from 16 and 18 suggest that the test must be adapted to our context before using it for screening.

Disclosure Nothing to disclose